AccuStem Sciences, Inc. engages in medical practice activities. It owns the breast cancer diagnostic StemPrintER and the SPARE genomics-based personalized medicine business. The StemPrintER is a multi-gene prognostic assay intended to predict the risk of recurrence of R+/HER2- breast cancer, and Spare, a derivative of StemPrintER, combines StemPrintER with two clinical markers. The firm anticipates this prognostic test to be used in conjunction with clinical evaluation to identify those patients at increased risk for early and late metastasis. The company was founded on June 5, 2020 and is headquartered in New York, NY.
Industry:
Pharmaceuticals Major